Caber-Med, Cabergoline, 1 mg, 60 Tabs

Cabergoline 1 mg tablets by Bioniche Pharma contain a potent, long-acting dopamine $D_2$ receptor agonist engineered to suppress pituitary prolactin secretion. By binding directly to dopamine receptors in the lactotroph cells of the anterior pituitary gland, Bioniche Pharma Cabergoline effectively lowers elevated circulating serum prolactin concentrations.

CLINICAL INDICATIONS

• Management of clinical hyperprolactinemia, encompassing both idiopathic hyperprolactinemia and prolactin-secreting pituitary adenomas (micro- and macroprolactinomas) using Bioniche Pharma Cabergoline.
• Therapeutic regulation of endocrine disruptions associated with hyperprolactinemia under direct medical supervision.

DOSAGE & ADMINISTRATION

Dosing regimes for Cabergoline 1 mg by Bioniche Pharma should be individually calculated and monitored under direct physician oversight. Treatment generally commences at low baseline doses with gradual titration guided by serum prolactin measurements and patient tolerance.

ADVERSE EFFECTS

Clinical observations indicate that most adverse events associated with Bioniche Pharma Cabergoline administration are dose-dependent and typically mild-to-moderate in severity:

Gastrointestinal & Metabolic:

• Nausea, emesis, dyspepsia, abdominal pain, flatulence, constipation, and xerostomia (dry mouth) reported during Bioniche Pharma Cabergoline therapy.

Neurological & Psychiatric:

• Cephalalgia (headache), lightheadedness, vertigo, somnolence, paresthesia, nervousness, and depressive symptoms experienced by patients receiving Bioniche Pharma Cabergoline.

Vascular & General Disturbances:

• Hot flashes, generalized fatigue, and transient orthostatic hypotensive fluctuations linked to Bioniche Pharma Cabergoline administration.

STORAGE & HANDLING

Store Bioniche Pharma Cabergoline in a dry, cool environment protected from direct light exposure and excess moisture. Keep strictly out of the reach and sight of children.